entertainment -WSS

entertainment

author：comprehensive 2025-09-30 23:04:24 - browse：74

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Former reverend arrested for allegedly killing 8

hotspot

WSS

Truvian presents data for its desktop blood

'Investigate these claims': UFO transparency at center of House hearing

Kellogg’s is going to war over Mexico’s nutrition label rules

How the drug

Senate panel puts off hardest PBM reforms for another day

Abortion policy in the spotlight at Republican debate

focus

entertainment

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How to make over

Tori Bowie and the unacceptable rates of Black maternal death

Democrats decry new health bill for going easy on private equity

New air purifier tech could be key to improving indoor air quality

Truvian presents data for its desktop blood

New air purifier tech could be key to improving indoor air quality

Study: Spinal cord stimulation helps patients with paralysis walk again

Novavax promises a turnaround & Lilly roils the obesity market

Kellogg’s is going to war over Mexico’s nutrition label rules

hotspot

What causes rare myocarditis in young men after Covid vaccines?

Former reverend arrested for allegedly killing 8

Roche’s Alnylam deal shows drug firms interested in heart drugs

In the gardens at Boston Children's Hospital, families find sanctuary

As obesity drug market grows, telehealth companies court payers

Device maker Teleflex to acquire urology company for $600M

entertainment

hotspot

focus

entertainment